Showing results (621-630 of 860) with videos related to

Sort By:
Pageof 86
Journal of Cardiovascular Pharmacology|January 1, 1989
Characteristics of the distribution of plasma atrial natriuretic peptides in a cross-sectional study of middle-aged untreated male workersF P Cappuccio, G A MacGregor, P Strazzullo, et al.
Leukemia & Lymphoma|January 1, 1995
Acute myeloid leukemias M2 potentially misdiagnosed as M3 variant French-American-Britain (FAB) subtype: a transitional form?S Fenu, D Carmini, F Mancini, et al.
The American Journal of Managed Care|April 10, 2020
High-cost, high-need patients: the impact of reported penicillin allergyKimberly G Blumenthal, Nicolas M Oreskovic, Xiaoqing Fu, et al.
Clinical Transplants|January 1, 1996
Two decades of cardiac transplantation at the Columbia-Presbyterian Medical Center: 1977-1997R E Michler, J M Chen, S Itescu, et al.
JAMA|February 2, 1990
Consumption of olive oil, butter, and vegetable oils and coronary heart disease risk factors. The Research Group ATS-RF2 of the Italian National Research CouncilM Trevisan, V Krogh, J Freudenheim, et al.
JAMA Network Open|April 4, 2024
SGLT2 Inhibitors, Functional Capacity, and Quality of Life in Patients With Heart Failure: A Systematic Review and Meta-AnalysisMichael Gao, Kirtipal Bhatia, Arjun Kapoor, et al.
Haematologica|December 1, 2001
Spontaneous remission in adult patients with de novo myelodysplastic syndrome: a possible eventM C Petti, R Latagliata, M Breccia, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 24, 2021
Association of Penicillin or Cephalosporin Allergy Documentation and Antibiotic Use in Hospitalized Patients with PneumoniaChristian M Mancini, Megan Wimmer, Lucas T Schulz, et al.
Pathology International|February 1, 1994
Expression of insulin-like growth factor II (IGF-II) in human hepatocellular carcinomas: an immunohistochemical studyA D'Errico, W F Grigioni, M Fiorentino, et al.
Tumori|August 31, 1987
Secondary acute non lymphoid leukemia in patients treated for non Hodgkin's lymphoma: no risk of therapy-related ANLL after PROVECIP scheduleG Cimino, A P Anselmo, C Cartoni, et al.
Pageof 86